Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.

Détails

ID Serval
serval:BIB_45AB1D850D02
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.
Périodique
Joint, bone, spine
Auteur⸱e⸱s
Cabrera N., Lega J.C., Kassai B., Wouters C., Kondi A., Cannizzaro E., Woerner A., Chausset A., Roethlisberger S., Jeanneret C., Aeschlimann F., Malik S., Duquesne A., Kaiser D., Higel L., Maes A., Berthet G., Hentgen V., Kone-Paut I., Belot A., Hofer M.
ISSN
1778-7254 (Electronic)
ISSN-L
1297-319X
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
86
Numéro
3
Pages
343-350
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To analyse and report the incidence of side effects of biological agents in paediatric patients with inflammatory diseases using of real-life follow-up cohort.
In this international, observational, retrospective, multicentre study of children treated by biological agents and followed in the Juvenile Inflammatory Rheumatism (JIR) cohort (JIRcohorte) network, a Kaplan-Meier method was used to estimate the occurrence of adverse events. A Cox model was constructed to identify independent predictors of adverse events.
Overall 813 patients totalling 3439 patients-year (PY) of biological agents were included. The main diagnosis was juvenile idiopathic arthritis (84%). A total of 222 patients (27.3%) had 419 adverse events, representing an incidence rate of 12.2 per 100 PY 95% CI [11.0; 13.4]. The overall incidence rate of serious adverse events was 3.9 per 100 PY 95% CI [3.2; 4.6]. Tocilizumab and infliximab were significantly associated with adverse events and canakinumab with serious adverse events. Univariate and multivariable analysis of adverse events and serious adverse events indicated that patients under biological agents with concomitant immunosuppressive drugs (excluding methotrexate) suffered from more of these events.
This study suggests an overall an acceptable safety of biologic agents in children with inflammatory rheumatic diseases treated with biological agents. However, the concomitant prescription of immunosuppressive drugs with biological agents represents a substantial risk of adverse events.
Mots-clé
Biological agents, JIRcohorte, adverse events, juvenile idiopathic arthritis, paediatric rheumatology, serious adverse events, Adverse events, Juvenile idiopathic arthritis, Paediatric rheumatology, Serious adverse events
Pubmed
Web of science
Création de la notice
19/09/2018 10:17
Dernière modification de la notice
04/01/2020 6:26
Données d'usage